MRK Quote, Financials, Valuation and Earnings

Biogen, Inc. has a net margin of 18.06% compared to Merck & Co., Inc.'s net margin of -2.24%. Merck & Co., Inc.'s return on equity of 39.63% beat Biogen, Inc.'s return on equity of 7.36%.

Merck & Co., Inc. has a consensus price target of $124.88, signalling upside risk potential of 2.86%. On the other hand Biogen, Inc. has an analysts' consensus of $205.52 which suggests that it could grow by 4.58%. Given that Biogen, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Biogen, Inc. is more attractive than Merck & Co., Inc..

Merck & Co., Inc. has a beta of 0.280, which suggesting that the stock is 72.042% less volatile than S&P 500. In comparison Biogen, Inc. has a beta of 0.160, suggesting its less volatile than the S&P 500 by 84.033%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 2.7%. Biogen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 45.05% of its earnings as a dividend. Biogen, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $16.4B, which are larger than Biogen, Inc. quarterly revenues of $2.2B. Merck & Co., Inc.'s net income of $3B is higher than Biogen, Inc.'s net income of -$48.9M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 16.69x while Biogen, Inc.'s PE ratio is 22.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.68x versus 3.03x for Biogen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cidara Therapeutics, Inc. has a net margin of 18.06% compared to Merck & Co., Inc.'s net margin of -30201.66%. Merck & Co., Inc.'s return on equity of 39.63% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Merck & Co., Inc. has a consensus price target of $124.88, signalling upside risk potential of 2.86%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.05%. Given that Merck & Co., Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Merck & Co., Inc. is more attractive than Cidara Therapeutics, Inc..

Merck & Co., Inc. has a beta of 0.280, which suggesting that the stock is 72.042% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.561, suggesting its more volatile than the S&P 500 by 56.074%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 2.7%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 45.05% of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $16.4B, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Merck & Co., Inc.'s net income of $3B is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 16.69x while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.68x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of 18.06% compared to Merck & Co., Inc.'s net margin of -19.69%. Merck & Co., Inc.'s return on equity of 39.63% beat Moderna, Inc.'s return on equity of -30.18%.

Merck & Co., Inc. has a consensus price target of $124.88, signalling upside risk potential of 2.86%. On the other hand Moderna, Inc. has an analysts' consensus of $39.00 which suggests that it could fall by -7.65%. Given that Merck & Co., Inc. has higher upside potential than Moderna, Inc., analysts believe Merck & Co., Inc. is more attractive than Moderna, Inc..

Merck & Co., Inc. has a beta of 0.280, which suggesting that the stock is 72.042% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 2.7%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Merck & Co., Inc. pays 45.05% of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $16.4B, which are larger than Moderna, Inc. quarterly revenues of $1B. Merck & Co., Inc.'s net income of $3B is higher than Moderna, Inc.'s net income of -$200M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 16.69x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.68x versus 7.33x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of 18.06% compared to Merck & Co., Inc.'s net margin of 21.74%. Merck & Co., Inc.'s return on equity of 39.63% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Merck & Co., Inc. has a consensus price target of $124.88, signalling upside risk potential of 2.86%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 8.08%. Given that Regeneron Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Regeneron Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..

Merck & Co., Inc. has a beta of 0.280, which suggesting that the stock is 72.042% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Merck & Co., Inc. has a quarterly dividend of $0.85 per share corresponding to a yield of 2.7%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Merck & Co., Inc. pays 45.05% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Merck & Co., Inc. quarterly revenues are $16.4B, which are larger than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Merck & Co., Inc.'s net income of $3B is higher than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Merck & Co., Inc.'s price-to-earnings ratio is 16.69x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Merck & Co., Inc. is 4.68x versus 6.08x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.